Prochlorperazine buccal
| Prochlorperazine buccal | |
| What is it? | Anti-emetic |
| Mechanism of action | Antagonist to: D2, 5HT (2A and 2C), H1 and α1, and muscarinic receptors |
| Starting dose | 3mg to 6mg every 12 hours17 |
| Time to maximal effect | 8 hours (4 hours with regular dosing) |
| Formulation | 3 mg orodispersible tablets (Buccastem) |
| Indication | Dizziness, nausea |
| Common adverse effects | ‘Agitation; amenorrhoea; arrhythmias; constipation; dizziness; drowsiness; dry mouth; erectile dysfunction; galactorrhoea; gynaecomastia; hyperprolactinaemia; hypotension (dose-related); insomnia; leucopenia; movement disorders; neutropenia; parkinsonism; QT interval prolongation; rash; seizure; tremor; urinary retention; vomiting; weight increased’16 |
| Contraindications | ‘Central nervous system depression; comatose states; phaeochromocytoma”16 |
| Caution | Photosensitivity |
| Licencing | Licensed formulation |
| Benefits | Buccal alternative anti-emetic, widely used in clinical practice |
| Risks | Oral and skin reactions possible, constipating |
| Cost | £27.61 for 50×3 mg buccal tablets |